Working Group 4

Policy Regulation and Impact Analysis Across Europe

wORKING GROUP 4

Policy Regulation and Impact Analysis Across Europe

Working Group 4 addresses the regulatory, economic, and policy dimensions of pharmacogenomics implementation in cardiovascular care. The group analyzes existing frameworks across European countries and identifies barriers to harmonization and large-scale adoption.

Prof. Damir Marjanović

Institute for Anthropological Research

A key focus is the evaluation of the economic impact of PGx, including potential cost savings from reduced adverse drug reactions and improved therapy outcomes. WG4 also examines regulatory guidelines, data-sharing challenges, and cross-border collaboration requirements.

Through policy recommendations and stakeholder engagement, this working group supports the development of a unified European approach to pharmacogenomics, ensuring equitable access and sustainable integration into healthcare systems.